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Objectives. We aimed to validate contrast-enhanced echocardi-
ography (CE) in the quantification of microvascular obstruction
(MO) against magnetic resonance imaging (MRI) and the his-
topathologic standards of radioactive microspheres and
thioflavin-S staining. We also determined the time course of MO
at days 2 and 9 after infarction and reperfusion.
Background. Postinfarction MO occurs because prolonged isch-
emia produces microvessel occlusion at the infarct core, prevent-
ing adequate reperfusion. Microvascular obstruction expands up
to 48 h after reperfusion; the time course beyond 2 days is
unknown. Though used to study MO, CE has not been compared
with MRI and thioflavin-S, which yield precise visual maps of MO.
Methods. Ten closed-chest dogs underwent 90-min coronary
artery occlusion and reperfusion. Both CE and MRI were per-
formed at 2 and 9 days after reperfusion. The MO regions by both
methods were quantified as percent left ventricular (% LV) mass.
Radioactive microspheres were injected for blood flow determina-
tion. Postmortem, the myocardium was stained with thioflavin-S
and 2,3,5-triphenyltetrazolium chloride.
Results. Expressed as % total LV, MO by MRI matched in size
MO by microspheres using a flow threshold of <40% remote
(4.96 6 3.52% vs. 5.32 6 3.98%, p 5 NS). For matched LV cross
sections, MO by CE matched in size MO by microspheres using a
flow threshold of <60% remote (13.27 6 4.31% vs. 13.5 6 4.94%,
p 5 NS). Both noninvasive techniques correlated well with
microspheres (MRI vs. CE, r 5 0.87 vs. 0.74; p 5 NS). Microvas-
cular obstruction by CE corresponded spatially to MRI-
hypoenhanced regions and thioflavin-negative regions. For
matched LV slices at 9 days after reperfusion, MO measured
12.94 6 4.51% by CE, 7.11 6 3.68% by MRI and 9.18 6 4.32% by
thioflavin-S. Compared to thioflavin-S, both noninvasive tech-
niques correlated well (CE vs. MRI, r 5 0.79 vs. 0.91; p 5 NS).
Microvascular obstruction size was unchanged at 2 and 9 days
(CE: 13.23 6 4.11% vs. 12.69 6 4.97%; MRI: 5.53 6 4.94% vs.
4.68 6 3.44%; p 5 NS for both).
Conclusions. Both CE and MRI can quantify MO. Both corre-
late well with the histopathologic standards. While MRI can
detect regions of MO with blood flow <40% of remote, the
threshold for MO by CE is <60% remote. The extent of MO is
unchanged at 2 and 9 days after reperfusion.
(J Am Coll Cardiol 1998;32:1756–64)
©1998 by the American College of Cardiology
Reperfusion therapy has significantly improved survival follow-
ing acute myocardial infarction (MI) (1,2). The mortality
reduction can be attributed to myocardial salvage (3,4). How-
ever, the benefits of late reperfusion are known. Studies
support the “open artery hypothesis” (5,6). Nonetheless, clin-
ically, it is difficult to gauge if “optimal reperfusion” has
occurred (7). A “patent” infarct-related epicardial coronary
artery by angiography is an inadequate marker of tissue-level
reperfusion (7,8). This arises from the inhomogeneity of
myocardial injury during ischemia which may preclude optimal
reperfusion because of microvessel occlusion.
In canines, Kloner et al. (9) demonstrated that 40 min of
ischemia, while causing irreversible myocyte injury, is well
tolerated by the capillary bed: no serious capillary damage or
perfusion defects result. With ischemia beyond 60 min, the
infarct core is characterized by injury of the endothelial cells
that form the intramyocardial capillaries (9). Examined by
electron microscopy, the microvessels are occluded by eryth-
rocytes, neutrophils and debris, such that even with epicardial
blood flow restoration, the infarct core will not reperfuse
(9,10). This area of microvascular obstruction (MO) is termed
the no-reflow region (9,10). Microvascular obstruction occurs
in humans and correlates with poorer global left ventricular
(LV) function (8,11) and more frequent post-MI complications
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(11,12). It thus has important prognostic significance after
acute MI.
Experimentally, radioactive microspheres have been the
“gold standard” for determining MO. Areas of MO have been
defined as regions with blood flow rates below 50% of the
remote region after reperfusion (13). Thioflavin-S has also
been used to depict MO (9,10) because it provides a precise
visual map of MO extent. Both methods, however, require
postmortem evaluation, precluding the serial examination of
MO in the same animal and application to humans. Recently,
the noninvasive technique of contrast-enhanced magnetic res-
onance imaging (MRI) was able to depict MO (12,14–16) and
validated against the histopathologic standards (15,16). While
contrast echocardiography (CE) has also been used to assess
microvascular integrity (8,11,17), its spatial location and extent
have not been validated against the histopathologic standards
or MRI. This study was designed to investigate this aspect.
Until recently, MO was felt to be fully established during
coronary occlusion, hence the term “no-reflow”. However, the
MO region has been shown to nearly triple in size from 2 min
to 3.5 h after reperfusion (10). Using MRI and radioactive
microspheres, we have shown further MO augmentation up to
48 h after reperfusion (18). The extent of MO beyond 2 days is
unknown. The temporal course of MO is important because
interventions that limit MO could improve post-MI prognosis
and add to the understanding of MI pathophysiology. Thus,
the validation of noninvasive techniques to quantify MO is
crucial.
Our study goals were as follows: 1) to validate the extent
and spatial location of MO by CE against the histopathologic
standards of microsphere blood flow and thioflavin-S; 2) to
compare the abilities of CE and MRI to quantify MO serially;
and 3) to use CE and MRI to further characterize the time
course of MO up to 9 days after infarction.
Methods
Experimental preparation. Ten mongrel dogs were stud-
ied. Experiments conformed to the “Position of the American
Heart Association on Research Animal Use” adopted in 1984.
Experimental myocardial infarction. Animals were anesthe-
tized and mechanically ventilated. Catheter sheaths were
placed in the right femoral artery and vein and in the carotid
artery. A 7F pigtail catheter was placed in the LV for radio-
active microsphere administration and pressure monitoring.
Three thousand units of intravenous heparin was given. A
2.5-cm angioplasty balloon was inflated to occlude the left
anterior descending artery (LAD) for 90 min and then deflated
for reperfusion. Both LAD occlusion and postreperfusion
patency were shown angiographically. The animals were al-
lowed to recover.
Day 2 after MI. Animals were anesthetized and mechani-
cally ventilated. Sheaths were placed in the left femoral vessels.
A pigtail catheter was placed in the LV for microsphere
administration and hemodynamic measurements.
Day 9 after MI. The protocol was similar to day 2, except
that the left carotid and jugular vessels were used.
Radioactive microspheres. Microspheres were used to mea-
sure regional blood flow. For each measurement, '2,000,000
sonicated microspheres (15 6 1 mm) labeled with 153Gd, 113Sn,
103Ru, 95Nb or 46Sc (DuPont) were injected into the left
ventricle. Starting before microsphere injection and continuing
for 2 min thereafter, arterial blood samples were withdrawn at
a rate of 2.06 ml/min. Flow was determined at five time points:
baseline, preceding coronary occlusion, 70 min after coronary
occlusion, and 30 min, 2 days and 9 days after reperfusion.
Contrast-enhanced echocardiography protocol. Contrast-
enhanced echocardiography was performed at days 2 and 9
after MI, after microsphere injections but before MRI, in
seven dogs. Animals were placed in the left lateral decubitus
position. Images were obtained with a Hewlett-Packard Sonos
500, 2.5 MHz transducer. At the first imaging session for each
animal, gain settings were optimized and maintained through-
out the protocol. At each session, two end diastolic short-axis
images, one at the midpapillary muscle level and one at the
midventricular level, were obtained. Imaging began '20 s
before contrast injection and continued for '45 to 60 s. Three
to five milliliters of Albunex (Mallinckrodt Medical, Inc.) were
bolus injected into a 7F pigtail catheter positioned in the aortic
outflow tract just distal to the valve leaflets.
MRI protocol. Images were acquired at 2 and 9 days after
MI using a 1.5T whole body magnet (Signa, General Electric)
and the contrast agent, Magnevist (gadopentetate dimeglu-
mine, Berlex Laboratories). Animals were placed in the left
lateral decubitus position with a flexible radiofrequency coil
(GP-FLEX) wrapped around the chest. We used a fast
gradient-echo imaging pulse sequence, SPGR (Spoiled Gradi-
ent Recall Acquisition in Steady State-GRASS) (19). Param-
eters were matrix size 5 256 3 108, field of view 5 32 cm,
TR 5 6.5 ms, TE 5 2.3 ms, flip angle 5 45° and voxel size 5
1.2 mm 3 3.3 mm 3 10.0 mm. Middiastolic images were
acquired during mechanical ventilation cessation. Breathholds
lasted 20 to 30 s. Between breathholds, animals were ventilated
for 30 s. The protocol began with a venous injection of
Magnevist (0.225 mmol/kg), continuing for 15 min thereafter.
One third of k space was acquired during each cardiac cycle
(central third acquired first, 36 phase-encodes/heartbeat), with
four to five base-to-apex short-axis cross sections imaged four
times/breathhold.
Contrast-enhanced echocardiography data analysis. Im-
ages were analyzed without postprocessing by two observers
Abbreviations and Acronyms
CE 5 contrast-enhanced echocardiography
LAD 5 left anterior descending artery
LV 5 left ventricular
MI 5 myocardial infarction
MO 5 microvascular obstruction
MRI 5 magnetic resonance imaging
TTC 5 2,3,5-triphenyltetrazolium chloride
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blinded to MRI and postmortem data. Images early after
contrast injection, that is, within 10 cardiac cycles, were chosen.
For each slice, the contrast defect, endocardial and epicardial
contours were planimetered with the aid of computer software
(Sigma-Scan-V3.90, Jandel Scientific). The contrast defect was
expressed as percent LV (% LV) myocardial area in that slice.
MO quantification by CE was compared to MRI (Fig. 1) and
thioflavin-S on a slice-by-slice basis. Because the entire LV was
imaged by MRI and studied by histopathologic methods, the
slices which best matched the CE cross sections were chosen
using anatomical landmarks (i.e., papillary muscles and right
ventricular insertions). To assess MO time course, the two CE
slices from day 2 were compared with corresponding slices
from day 9.
Magnetic resonance imaging data analysis. Images were
analyzed sequentially from baseline, before contrast, to 15 min
after contrast injection with software package NIH IMAGE
(National Institutes of Health, Bethesda, Maryland). Three
patterns of myocardial signal enhancement were identified, as
earlier described (14,15). In noninfarcted myocardium, signal
intensity rises rapidly in the first minute after contrast injection
and then decays over 10 to 15 min. Infarcted myocardium
generates signal that also rapidly gains in intensity during the
first minute after contrast but which continues to increase for
2 to 3 min before slowly decaying. This causes hyperenhance-
ment of infarcted relative to normal myocardium during the 10
to 15 min after contrast injection. The third pattern is that of
a gradual increase in signal intensity over the first 3 min after
contrast injection. Such areas are hypoenhanced relative to
surrounding myocardium and correspond to regions of MO or
“no reflow” (15,16,18). Hypoenhancement persists for '1 min
and is located in the subendocardium of the infarct core.
Microvascular obstruction extent. The MO region was iden-
tified from early images showing distinct hypoenhancement per-
sisting for $1 min. The hypoenhanced area was planimetered for
each base-to-apex short-axis slice. Microvascular obstruction ex-
tent, expressed as % total LV mass, was calculated based on the
percent of hypoenhancement in each slice, weighted according to
slice cross-sectional area. For all slices, MO size 5 ((%
hypoenhanced)(cross-sectional area)/((cross-sectional area).
Infarct size. The hyperenhanced region was identified from
images obtained 5 to 10 min after contrast. The area of
hyperenhancement was planimetered for each base-to-apex
short-axis slice. Infarct size, expressed as % total LV mass, was
calculated based on the percent of hyperenhancement in each
slice, weighted according to slice cross-sectional area. Thus, for
all slices, infarct size 5 ((% hyperenhanced)(cross-sectional
area)/((cross-sectional area).
Postmortem measurement of MO, infarct and risk regions.
Microvascular obstruction and infarct size. After day 9 imaging,
20 ml of 4% thioflavin-S solution was injected into the left
ventricle. The hearts were then arrested with potassium chlo-
ride and excised. The epicardial fat, atria, right ventricular free
wall and valvular apparatus were removed. The left ventricle
was sectioned into four to five short-axis slices. Each slice
(apical side) was viewed under ultraviolet light and the
thioflavin-negative (MO) region (9,10) and myocardial borders
were traced on clear acetate sheets. The slices were incubated
in 2,3,5-triphenyltetrazolium chloride (TTC) 2% solution for
20 min at 37°C. They were then viewed under room light to
Figure 1. Corresponding CE and MR images. The CE defect matches
in spatial extent the MRI hypoenhanced region. Both the CE defect
and MRI hypoenhanced region are in the same location as the MRI
hyperenhanced area, but are smaller.
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delineate the TTC-negative (infarcted) region (20) which was
traced on clear acetate sheets. From the drawings, the
thioflavin-negative, TTC-negative and LV myocardial areas
were planimetered (Sigma-Scan-V3.90, Jandel Scientific) for
each slice. MO extent and infarct size were calculated as %
total LV mass: % region of interest 5 ((% region of
interest)(cross-sectional area)/((cross-sectional area).
Microsphere blood flow analysis. After MO and infarct size
determination, the LV slices were sectioned into pie-shaped
wedges which were then subdivided into five equal regions
from endocardium to epicardium, yielding '350 myocardial
samples/heart. Each sample was weighed, its location recorded
and then counted in a gamma emission well spectrometer
(Cobra II, Hewlett-Packard). Regional blood flow was calcu-
lated by standard methods (21,22).
To calculate blood flow, myocardial samples were grouped
into four regions: remote (LV wall opposite that of the
infarct); thioflavin-negative (MO); thioflavin-positive/TTC-
negative (infarcted); and noninfarcted risk (TTC-positive with
blood flow ,50% of remote during coronary occlusion). The
risk region, expressed as % total LV weight, was quantified by
summing the weights of all samples with blood flow ,50% of
remote during coronary occlusion.
The extent of regions receiving blood flow ,40%, ,50%
and ,60% of remote was also determined at days 2 and 9 after
MI. The weights of all myocardial samples contained within
the TTC-negative region with flow below a defined threshold
(i.e., 40%, 50% or 60%) were summed and expressed as %
total LV weight both on a slice-to-slice basis and for the entire
left ventricle.
Statistical analysis. Microvascular obstruction extents by
the various methods were compared with repeated-measures
one-way analysis of variance (23). Differences between pairs of
methods were isolated with Bonferroni t tests (23). Linear
regression analyses (24) were used to compare the methods of
quantifying MO and infarct size. Serial changes in MO extent,
infarct size and regional blood flow were compared with paired
t tests (23). Fisher’s z transformation (24) was used to test pairs
of correlation coefficients. Results are reported as mean 6 SD
with p values ,0.05 considered significant.
Results
Hemodynamics. Table 1 summarizes the hemodynamic
measurements observed during the protocol. The changes
were typical of those seen during acute MI and reperfusion. As
documented previously, Albunex did not significantly alter
hemodynamics (25).
Myocardial blood flow. Figure 2 shows myocardial blood
flow rates (relative to remote areas) in the regions of 1) MO
(thioflavin-negative) and 2) infarcted with patent microvascu-
lature (thioflavin-positive/TTC-negative). At baseline, the re-
gions had similar flow. With occlusion, flow to both regions
declined (p , 0.01). As expected, region 1 (MO) had lower














Systolic BP (mm Hg) 128 6 13 111 6 13 111 6 17 118 6 14 122 6 17 106 6 8 107 6 17
Diastolic BP (mm Hg) 91 6 12 77 6 14 74 6 13 76 6 15 76 6 17 76 6 11 80 6 16
Mean BP (mm Hg) 103 6 12 88 6 14 87 6 14 90 6 13 91 6 17 86 6 9 89 6 15
Heart rate (beats/min) 115 6 15 107 6 17 101 6 24 118 6 22 120 6 20 115 6 15 103 6 8
Abbreviations: BP 5 blood pressure; CE 5 contrast-enhanced echocardiography.
Figure 2. Regional blood flow. The asterisk de-
notes the significant difference in flows between
MO and infarcted (microvasculature intact) re-
gions at the same timepoint. Microvascular ob-
struction and infarcted regions had similar base-
line flows. At occlusion, flow to MO regions was
lower than to regions that become infarcted but
whose microvasculatures remain intact (p 5
0.0002). With reperfusion, blood flow in both
regions returns to baseline. At day 2, MO regions
have lower blood flow than infarcted areas (p ,
0.0001). At day 9, MO regions continue to have
flow that is lower than infarcted areas (p ,
0.0001). Within each region, flow rates at days 2
and 9 are similar (p 5 NS).
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flow (p 5 0.0002) than region 2 (infarcted territory outside the
MO region). Thirty minutes after reperfusion, flow to both
regions returned to levels similar to baseline (p 5 NS),
indicating successful reperfusion. At 2 days after reperfusion,
both regions had flow rates below baseline (p , 0.004 for
both). Region 1 (MO) had lower flow than region 2 at 2 days
(p , 0.0001). By 9 days after reperfusion, both regions
continued to have flow below baseline (p , 0.007 for both).
Region 1 (MO) had lower flow than region 2 at 9 days (p ,
0.0001). Flow to region 1 (MO) was similar at 2 and 9 days
after reperfusion (p 5 NS), as was flow to region 2 (p 5 NS).
Quantification of MO by microspheres—comparison with
MRI, CE and thioflavin-S. Microvascular obstruction by MRI
(% total LV) measured 4.96 6 3.52% versus microsphere-
determined areas of 5.32 6 3.98% (flow threshold of ,40% of
remote), 7.49 6 4.54% (threshold of ,50%) and 10.57 6
5.62% (threshold of ,60%). Microvascular obstruction by
MRI was similar in extent to regions with ,40% of remote
flow (p 5 NS), but smaller than areas with ,50% (p 5 0.001)
and ,60% (p , 0.0001). Microvascular obstruction by MRI
correlated with MO by microspheres (Fig. 3).
For matched LV cross sections, MO by CE measured
13.27 6 4.31% versus microsphere-determined regions of
6.62 6 4.61% (threshold of ,40% of remote flow), 9.51 6
4.45% (threshold of ,50%) and 13.5 6 4.94% (threshold of
,60%). Microvascular obstruction by CE was larger than areas
with ,40% (p , 0.0001) and ,50% (p 5 0.0001) of remote
flow. Microvascular obstruction by CE was similar in size to
regions with ,60% of remote flow (p 5 NS). Microvascular
obstruction by CE correlated with MO by microspheres (Fig.
3).
For the total left ventricle, MO extent by thioflavin-S was
9.05 6 5.48% compared with 5.67 6 3.89% (threshold of
,40%), 8.01 6 4.55% (threshold of ,50%) and 11.33 6
5.25% (threshold of ,60%). Microvascular obstruction by
thioflavin was larger than regions with ,40% (p 5 0.0018),
smaller than regions with ,60% (p 5 0.0092) and similar in
size to regions with ,50% (p 5 NS) of remote flow. Micro-
vascular obstruction by thioflavin correlated well with MO by
microspheres (r 5 0.96, y 5 1.16320.22, SEE 5 2.17, p 5
0.0001).
The correlation between MRI and microspheres (r 5 0.87)
was similar to (p 5 NS) that between CE and microspheres
(r 5 0.74). In contrast, the correlation between CE and
microspheres was less robust than that between thioflavin-S
and microspheres (r 5 0.74 vs. 0.96, p 5 0.0244). The
correlation between MRI and microspheres versus thioflavin
and microspheres was statistically similar (r 5 0.87 vs. 0.96, p 5
NS).
Quantification of MO by CE, MRI and thioflavin-S. Figure
4 shows two typical CE images with corresponding MR images
and thioflavin-stained slices. The spatial location of the CE
defects correlates with the MRI hypoenhanced and the
thioflavin-negative regions.
For matched LV cross sections at day 9 after MI, MO
measured 12.94 6 4.51% by CE, 7.11 6 3.68% by MRI and
9.18 6 4.34% by thioflavin (repeated-measures analysis of
variance, F 5 22.8, p , 0.001). Microvascular obstruction by
CE was larger than by MRI (t 5 6.63, p , 0.001) and by
thioflavin-S (t 5 4.41, p , 0.001). Microvascular obstruction by
MRI was smaller than by thioflavin-S (t 5 2.21, 0.01 , p ,
0.025).
For matched slices, MO by CE correlated with thioflavin-S
but overestimated it by 68% (Fig. 5). Compared to MO by CE
for matched slices, MO by MRI was 60% as large and was
modestly correlated (Spearman r 5 0.63, y 5 0.68317.76,
SEE 5 7.03, p 5 0.0017). When calculated as % total LV mass,
extent of MRI MO (5.42 6 3.62%) was 61% of thioflavin-S
(9.00 6 4.84%) and the two were well correlated (Fig. 5).
Compared to the correlation between MRI and thioflavin, the
correlation between CE and thioflavin was similar (r 5 0.91 vs.
0.79, p 5 NS).
Infarct size by MRI and 2,3,5-triphenyltetrazolium chlo-
ride. Infarct size (% total LV mass) was 24.97 6 9.28% by
MRI and 18.40 6 8.38% by 2,3,5-triphenyltetrazolium chloride
(TTC). The risk region by microspheres was 41.20 6 8.34%.
For measuring infarct size, MRI and TTC correlated well (r 5
0.91, y 5 1.01316.36, SEE 5 2.65, p 5 0.0002). Relative to
the risk region, MRI infarct size was 55% as large and was
highly correlated (Spearman’s r 5 0.97, y 5 0.893213.3,
SEE 5 6.87, p , 0.0001). The TTC region was 42% of the risk
Figure 3. Correlation between MO by noninvasive techniques versus
radioactive microspheres.
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region and correlated well (Spearman’s r 5 0.93, y 5
0.923220.2, SEE 5 8.94, p , 0.002).
Microvascular obstruction extent and infarct size at 2 and
9 days after MI. Figure 6 depicts the time course of MO
extent by CE and MRI. The extent of MO (% LV cross-
sectional area) by CE was 13.23 6 4.11% and 12.69 6 4.97%
(p 5 NS) at 2 and 9 days after MI. By MRI, MO extent
(% total LV mass) was 5.53 6 4.94% and 4.68 6 3.44% (p 5
NS). Similarly, infarct size by MRI (% total LV mass) did not
change significantly (Fig. 6), measuring 28.41 6 6.71% and
25.78 6 9.46% at 2 and 9 days (p 5 NS).
Microsphere-determined regions of MO (% total LV) did
not change over time. At 2 versus 9 days, the MO region was
4.98 6 3.44% versus 4.70 6 2.98% (p 5 NS) using a threshold
of ,40%; 7.47 6 4.43% versus 6.93 6 3.85% (p 5 NS) for a
threshold of ,50%, and 10.34 6 5.98% versus 9.53 6 4.49%
(p 5 NS) for a threshold of ,60%.
Discussion
To our knowledge, this is the first study to directly quantify
the extent of postinfarction MO by CE and compare it with the
methods of radioactive microspheres and thioflavin-S and with
contrast-enhanced MRI. This is also the first investigation of
MO time course beyond 3 days after coronary occlusion and
reperfusion (26). Microvascular obstruction by CE corre-
sponds in spatial location to MO by MRI and thioflavin.
However, the size of the regions differ: MO by CE is larger
than MO by thioflavin, which in turn is larger than MO by
MRI. The size differentials can be explained by corresponding
microsphere “maps” which quantify the extent of regions with
varying thresholds of blood flow. While MRI detects a region
of MO receiving blood flow ,40% of remote, the threshold for
Figure 5. Correlation between MO by noninvasive techniques versus
thioflavin-S.
Figure 4. The CE images from separate animals (A and B) are
compared to matched MR images and postmortem thioflavin-S stained
slices. The CE defects correspond in location to MO defined by MRI
hypoenhancement and thioflavin-negative regions.
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CE detection is ,60% of remote. The threshold for lack of
thioflavin-S uptake is ,50% of remote. Despite the disparity in
thresholds, CE and MRI correlated equally well with radioac-
tive microspheres in MO quantification. However, CE corre-
lated less well with microspheres than did thioflavin-S. In
contrast, MRI correlated equally well with microspheres as
thioflavin-S. Lastly, though MO size expands up to 48 h after
reperfusion, as documented previously (10,18), this study
shows that at 2 and 9 days after reperfusion, MO extent is
similar.
Rationale for differences between CE and MRI. Although
both CE and MRI can effectively measure MO, they have
different thresholds for detecting flow reduction. Several po-
tential explanations exist. Gadolinium rapidly extravasates
from the blood pool into the interstitium and hence, is an
interstitial agent. Microbubbles, however, are purely intravas-
cular. Because gadolinium can penetrate into extravascular
spaces and travel where bubbles cannot, one may thus expect
MRI hypoenhancement to be smaller than the CE defect.
Different physical properties of the agents may also contribute.
Albumin microbubbles are, on average, larger than gadolinium
molecules. Moreover, Albunex is a heterogeneous population
of bubbles with variable diameters (27), while gadolinium
molecules are uniform. As such, microbubbles larger than
gadolinium molecules could become temporarily lodged in
microvessels that would allow passage of gadolinium. Thus, the
region void of Albunex bubbles should theoretically be larger
than the MRI hypoenhanced region. It is also possible that
differences in perception threshold underlie disparities in MO
measurement. Similar to our findings, Judd et al. (15) showed
that MO by MRI corresponded in size to regions with blood
flow much less than that measured by thioflavin-S. Given the
similar molecular weights of gadolinium and thioflavin-S, the
discrepancy between the techniques may be one of perception
threshold: a higher concentration of thioflavin-S may be re-
quired before the myocardium appears fluorescent (i.e., well-
perfused). Analogously, compared to gadolinium, more Albu-
nex microbubbles may be needed to enhance myocardium and
hence, there is a higher threshold for distinguishing between
normal and underperfused regions by CE.
Ultrasound destruction of microbubbles has been reported
(28). Larger CE defects may theoretically result from this
phenomenon. This effect, however, is minimal with intraaortic
root contrast injections (28), which was the route used in our
study. On the other hand, intracoronary Albunex can attenuate
images because of high microbubble concentrations. We min-
imized this with intraaortic root injections and optimal Albu-
nex dosing. Nonetheless, our results are likely specific for the
particular contrast agent used. The extent of MO will depend
on the size distribution of the microbubble population. Other
agents have many more bubbles measuring 5 to 15 mm in
diameter compared with Albunex (27). These larger micro-
bubbles may theoretically become temporarily lodged in mi-
crovessels and prevent the passage of the smaller micro-
bubbles, creating a measured CE defect that is larger than that
of Albunex.
Study limitations. Advances in technology may enhance
the ability of CE to quantify MO. Our CE protocol used
fundamental imaging and no data postprocessing. Although
harmonic imaging improves the signal-to-noise ratio (29,30), it
Figure 6. The CE and MR images from the same animal at 2 and 9
days after reperfusion. The CE defects correspond spatially to the
regions of MRI hypoenhancement; both do not significantly change
over time. The region of MRI hyperenhancement (infarct size) is
larger than MO and also does not change over time.
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is not always appreciably different from fundamental imaging
(e.g., infarct size measurement [30]). We also used intraaortic
root injections of Albunex. Contrast agents which limit pulmo-
nary elimination (27,31,32), coupled with harmonic imaging
and continuous contrast administration (33), may improve the
accuracy of MO detection and perhaps allow its quantification
from intravenous contrast injections.
A second limitation lies in the method by which imaging
and histopathologic data were cross registered. Methods of
cross registering images obtained by different techniques are
suboptimal because of disparities in magnification. While we
superimposed transparencies of the CE images, MR images
and histopathologic drawings to ensure qualitative concor-
dance of the MO regions, quantitative comparisons were
performed as described, in keeping with methodology utilized
previously by our group (18).
Advantages of MRI. This study highlights several advan-
tages of MRI. Magnetic resonance imaging allows precise
multislice imaging, enabling one to measure MO relative to the
entire left ventricle. In contrast, imaging more than two
anatomically unique slices by CE is difficult and thus, MO by
CE cannot be accurately measured for the whole left ventricle.
Regions of MO by MRI are also visually more distinct.
Because of greater spatial resolution, MRI can better define
the borders of the MO region. Lastly, infarct size is readily
available with MRI: hyperenhanced regions correspond to
infarcted areas (14,15). With CE, coronary vasodilators are
required for infarct size estimation (30).
Contrast-enhanced echocardiography versus MRI. It is
unclear whether MO quantification is “better” by CE or by
MRI. Contrast-enhanced echocardiography detects a less se-
vere flow reduction than MRI. As markers for degree of
microvascular damage, CE can perhaps be seen as more
sensitive and MRI as more specific. Within the infarct core,
Ambrosio et al. (10) noted severe endothelial cell injury and
intracapillary erythrocyte stasis. In adjacent regions, less dam-
aged endothelial cells were interspersed with areas with nor-
mal microvessels (10). Hence, the infarct core is likely charac-
terized by complete microvessel occlusion. Surrounding it are
rims of tissue that have progressively less obstructed microves-
sels with gradual interspersion of areas with normal microvas-
culature. Contrast-enhanced echocardiography may thus de-
tect lesser degrees of microvascular damage than MRI.
Nonetheless, this difference may not be clinically important.
The prognostic value of MO size may lie in the relative areas
by one technique: a large MO region by either CE or MRI may
portend a poorer prognosis than a small region by the same
technique. Further studies are needed.
Microvascular obstruction time course. The other finding
of our study is that the process causing MO expansion early
after reperfusion stabilizes between days 2 and 9 after reper-
fusion. As we quantitated MO at only two timepoints, we
cannot definitively plot the course of MO extent between days
2 and 9. Indirect evidence, however, suggests that MO extent
recedes after day 9. We previously studied patients by MRI 6
months after MI (12). No patients who had MO by MRI
acutely after infarct had evidence of it on 6-month follow-up.
Thus, by 6 months, the region of MO has resolved.
With the results of this study and prior work (10,18), one
may postulate the time course of MO extent after infarction
and reperfusion as progressively increasing, peaking at 2 days
after MI; plateau and stabilization in the week thereafter; and
gradual recanalization of occluded microvessels causing a
progressive decline with eventual disappearance of MO during
infarct healing. Implications of this proposed time course for
future investigations are numerous. Strategies to prevent MO
or hasten its regression may improve prognosis by limiting
post-MI remodeling and accelerating infarct healing. Such
studies could add insight into the pathophysiologic mecha-
nisms of acute coronary thrombosis and reperfusion.
Conclusions. Both CE and MRI can quantify MO. They
are both potentially useful techniques for serially measuring
MO extent. They differ in their thresholds to detect reduction
in blood flow. With either imaging technique, however, the
extent of MO remains unchanged at 2 and 9 days after MI.
Therefore, in assessing post-MI prognosis, MO can be studied
noninvasively up to at least 1 week after acute MI.
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